Author

Galyna Myshanych

OpenAlex ID: A5082640973

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

2021 · Matthias von Herrath, Stephen C Bain, et al. · The Lancet Diabetes & Endocrinology · 199

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Rodica Pop-Busui, Søren Rasmussen, et al. · JAMA Internal Medicine · 18

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial

2025 · Stephen J. Nicholls, Donna H. Ryan, et al. · JAMA Cardiology · 8

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Sharon L. Mulvagh, Silvio E. Inzucchi, et al. · JAMA Cardiology · 6

Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial

2026 · John W. Ostrominski, Jorge Plutzky, et al. · JAMA Cardiology · 2

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Nikolaus Marx, John E. Deanfield, et al. · JAMA Cardiology

Works count: 6

Citation count: 233

H-index: 4

I10-index: 2